CANCER GENETIC COUNSELING IN EUROPE. PART II: CENTRAL AND EASTERN EUROPEAN COUNTRIES

  • Aliona MORARIU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Alina MANOLE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Doina AZOICAI “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Hereditary Breast and /or Ovarian Cancer (HBOC) is the leading cancer among women worldwide. Since the discovery of the BRCA mutation in the ´90s, several healthcare programs have been established in Western European countries. These programs provide nationwide access to individualized care for families at high risk for HBOC. The genetic counseling starts with mutations screening programs with a guideline for further management of the high-risk group for breast cancer. Unlike Western European in the case of Central and East European countries, genetic testing for mutations in BRCA1 and BRCA2 genes is limited due to the high costs not covered by the insurance funds. As an exception between Eastern European countries in the Czech Republic genetic counseling and testing for hereditary breast and/or ovarian cancer is available to all women who are at risk of developing an early onset disease. Because of limited resources the rest of Eastern European countries try to identify some specific solutions for overcome this problem. One solution implemented with success in Poland is to identify founder recurrent mutations in order to offer testing for these recurring mutations to a large population. The high frequency of 3 founder mutations in Polish women supports the implementation of a national program that provides genetic counseling and testing with significantly reduced costs. The same panel of BRCA1 founder mutations like for Poland, seems to be found in countries from Baltic sea region so the recommendation for national screening for these mutations in HBOC women exist since 2003. The other solution is to offer sequencing of the entire coding region of the gene, which is more precise and covers all mutations, to a highly selected and less numerous populations. For instance, in Romania, free genetic BRCA1 and BRCA2 genes testing and counseling is available only in some particular programs conducted in few Medical Centers, but Slovenia implemented a national program for genetic testing and counseling but restricted to EOC patients that were diagnosed with early onset high grade-serous EOC.

Author Biographies

Aliona MORARIU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Preventive Medicine and Interdisciplinarity

Alina MANOLE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Preventive Medicine and Interdisciplinarity

Doina AZOICAI, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Preventive Medicine and Interdisciplinarity

References

1. Goldberg JI, Borgen PI. Breast cancer susceptibility testing: past, present and future. Expert Review of Anticancer Therapy 2006; 6(8): 1205-1214.
2. Mavaddat N, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Nat Can Inst 2013; 105(11): 812-822.
3. Rhiem K, et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high-risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012; 14 (6): R156.
4. Gadzicki, et al. Genetic testing for familial/hereditary breast cancer - comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011; 2(2): 53-69.
5. Engel C, Zachariae S, Fischer C. Familiärer Brustkrebs-empirische Erkrankungsrisiken und Risikoberechnungsmodelle. Medizinische Genetik 2015; (2): 217-222.
6. Vetter L, et al. Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany. Breast Can Res Treat 2016; 156(2): 289-299.
7. Altobelli E, Lattanzi A. Breast cancer in European Union: An update of screening programmes as of March 2014 (review). Internat J Oncol 2014; 45(5): 1785-1792.
8. Autier P, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 2010; 341: c3620.
9. Vrdoljak, E, et al. Cancer control in Central and Eastern Europe: Current situation and recommendations for improvement. The Oncologist 2016; 21: 1183-1190.
10. Górski B, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004; 110(5): 683-686.
11. Menkiszak J, et al. Hereditary ovarian cancer in Poland. Int J Cancer 2003; 106(6): 942-945.
12. McCarthy AM, Armstrong K. The role of testing for BRCA1 and BRCA2 mutations in cancer prevention. JAMA Intern Med 2014; 174(7): 1023-1024.
13. Tihomirova L, et al. BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia. Advances in Medical Sciences 2014; 59 (1): 114-119.
14. Foretova, L, et al. Genetic and Preventive Services for Hereditary Breast and Ovarian Cancer in the Czech Republic. Hered Cancer Clin Pract 2006; 4(1): 3-6.
15. Markoff A, et al. Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols. Eur J Hum Genet 1998; 6(2):145-150.
16. Dodova RI, et al. Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients. BMC Cancer 2015; 17(15): 523.
17. Negura L, Uhrhammer N, Negura A, Artenie V, Carasevici E, Bignon YJ. Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population. Fam Cancer 2010; 9(4): 519-523.
18. Eniu A, et al. Understanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: First report on founder mutations in Romanians. Annals of Oncology 2017; 28(Suppl. 5): 1.
19. Cvelbar M, et al. Genetic counselling, BRCA1/2 status and clinico-pathologic characteristics of patients with ovarian cancer before 50 years of age. Radiol Oncol 2017; 51(2): 187-194.
20. Krajc M, et al. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 2008; 10(9): 83.
Published
2018-12-27